Stock listing
A2ALUN Stock Price, News, Filings & Events — Synact Pharma Ab
Selected listing: A2ALUN · LS · EUR · DE
This page tracks Synact Pharma Ab's A2ALUN:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2ALUN:LS. A2ALUN:LS is the stock-level entry point for investors researching Synact Pharma Ab, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
- Ticker
- A2ALUN:LS
- Asset type
- Stock
- Market cap
- $108.5M
- Sector
- Health Technology
- Industry
- Pharmaceuticals: Major
- Exchange
- LS
- Currency
- EUR
Synact Pharma Ab A2ALUN:LS stock context
This page tracks Synact Pharma Ab's A2ALUN:LS listing on LS in EUR for DE, including stock price context, company news, filings, investor events, AI research briefs, and market updates for investors following A2ALUN:LS. A2ALUN:LS is the stock-level entry point for investors researching Synact Pharma Ab, while company-level investor report content can remain shared across the same issuer's public listings. 6ix connects this selected listing to available company updates, filings, investor events, replay content, and AI research briefs so stock search leads to the relevant company context without making another exchange listing primary.
Latest news from Synact Pharma Ab
Further Analysis of the Phase 2b ADVANCE Study Reinforces Phase 2b EXPAND Results and Supports Phase 3 Development - FDA Discussions on T...
September 7, 2026
SynAct Pharma's CEO and CSO Sell Shares
September 3, 2026
SynAct Pharma : Phase 2b ADVANCE study demonstrates positive effects of resomelagon in Rheumatoid Arthritis - supports phase 3 design, re...
June 15, 2026
Notice of annual general meeting in SynAct Pharma AB
May 7, 2026
SynAct Pharma completes dosing in phase IIb ADVANCE study ahead of June readout
May 6, 2026
Research Synact Pharma Ab
Synact Pharma Ab investor report
Review AI stock analysis and investor report context for A2ALUN:LS.
Synact Pharma Ab company profile
View the public company page for Synact Pharma Ab on 6ix.
Synact Pharma Ab news
Read company news and market updates connected to Synact Pharma Ab.
Synact Pharma Ab investor events
Find investor webinars, events, and replay context for Synact Pharma Ab.
Alternate listings
SYNACT:OMXSTO
SE · SEK
Alternate listing for Synact Pharma Ab; the primary context on this page is A2ALUN:LS.
SYNACS:AQUISEU
GB · SEK
Alternate listing for Synact Pharma Ab; the primary context on this page is A2ALUN:LS.
A2ALUN:LSX
DE · EUR
Alternate listing for Synact Pharma Ab; the primary context on this page is A2ALUN:LS.
8F8:FWB
DE · EUR
Alternate listing for Synact Pharma Ab; the primary context on this page is A2ALUN:LS.
8F8:GETTEX
DE · EUR
Alternate listing for Synact Pharma Ab; the primary context on this page is A2ALUN:LS.
SYNACS:AQUISUK
GB · SEK
Alternate listing for Synact Pharma Ab; the primary context on this page is A2ALUN:LS.
8F8:MUN
DE · EUR
Alternate listing for Synact Pharma Ab; the primary context on this page is A2ALUN:LS.
8F8:SWB
DE · EUR
Alternate listing for Synact Pharma Ab; the primary context on this page is A2ALUN:LS.
8F8:TRADEGATE
DE · EUR
Alternate listing for Synact Pharma Ab; the primary context on this page is A2ALUN:LS.